Markets:

Overview

News

Currencies

International

Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

11.65 -0.19 (-1.60%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Arvinas, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 01, 2025

Via Benzinga

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

A Peek at Arvinas's Future Earnings ↗

April 30, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 30, 2025

Via Benzinga

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study ↗

April 04, 2025

Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for Parkinson's and PSP treatment.

Via Benzinga

These Analysts Revise Their Forecasts On Arvinas After Q4 Results ↗

February 12, 2025

Via Benzinga

What 4 Analyst Ratings Have To Say About Arvinas ↗

February 07, 2025

Via Benzinga

Demystifying Arvinas: Insights From 5 Analyst Reviews ↗

December 11, 2024

Via Benzinga

Unveiling 4 Analyst Insights On Arvinas ↗

November 20, 2024

Via Benzinga

Top 3 Health Care Stocks That Are Set To Fly This Month ↗

March 26, 2025

Via Benzinga

Tesla To $120? Here Are 10 Top Analyst Forecasts For Wednesday ↗

March 12, 2025

Via Benzinga

This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

March 12, 2025

Via Benzinga

Tuesday's session: top gainers and losers ↗

March 11, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

What's Next: Arvinas's Earnings Preview ↗

October 29, 2024

Via Benzinga

Critical Insights From Arvinas Analyst Ratings: What You Need To Know ↗

September 09, 2024

Via Benzinga

The Latest Analyst Ratings For Arvinas ↗

July 31, 2024

Via Benzinga

Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial ↗

March 11, 2025

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.

Via Benzinga

Gapping stocks in Tuesday's session ↗

March 11, 2025

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Crude Oil Gains 1%; Ciena Earnings Top Views ↗

March 11, 2025

Via Benzinga

Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug ↗

March 11, 2025

The companies are looking to use protein degradation to take on some forms of breast cancer.

Via Investor's Business Daily

Stay updated with the stocks that are on the move in today's pre-market session. ↗

March 11, 2025

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

US Stocks Mixed; Kohl's Shares Plunge After Q4 Results ↗

March 11, 2025

Via Benzinga

Snowflake To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

February 12, 2025

Via Benzinga

US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday? ↗

February 11, 2025

U.S.

Via Benzinga

Earnings Scheduled For February 11, 2025 ↗

February 11, 2025

Via Benzinga

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 ↗

January 21, 2025

Via The Motley Fool

Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients ↗

December 10, 2024

Arvinas and Pfizer share Phase 1b TACTIVE-U trial results showing 62.5% clinical benefit rate and tolerable safety for advanced breast cancer therapy.

Via Benzinga

ARVN Stock Earnings: Arvinas Beats EPS, Beats Revenue for Q2 2024 ↗

July 30, 2024

ARVN stock results show that Arvinas beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Biotech Arvinas Stock Earns 82 RS Rating ↗

July 17, 2024

The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82.

Via Investor's Business Daily

Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 16, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Arvinas, Inc. - Common Stock (NQ:ARVN)

Headline News about Arvinas, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today